Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis

This article was published in the following Dove Press journal:
International Journal of Nanomedicine

Xinquan Liu
Debadyuti Ghosh

Division of Molecular Pharmaceutics and
Drug Delivery, College of Pharmacy, The
University of Texas at Austin, Austin, TX
78712, USA

Background: The *RAS* family of oncogenes (*KRAS*, *HRAS*, *NRAS*) are the most frequent mutations in cancers and regulate key signaling pathways that drive tumor progression. As a result, drug delivery targeting *RAS*-driven tumors has been a long-standing challenge in cancer therapy. Mutant *RAS* activates cancer cells to actively take up nutrients, including glucose, lipids, and albumin, via macropinocytosis to fulfill their energetic requirements to survive and proliferate.

Purpose: We exploit macropinocytosis pathway to deliver nanoparticles (NPs) in cancer cells harboring activating *KRAS* mutations.

Methods: NPs were synthesized by the desolvation method. The physicochemical properties and stability of NPs were characterized by dynamic light scattering and transmission electron microscopy. Uptake of fluorescently labelled NPs in wild-type and mutant *KRAS* cells were quantitatively determined by flow cytometry and qualitatively by fluorescent microscopy. NP uptake by *KRAS*-driven macropinocytosis was confirmed by pharmacological inhibition and genetic knockdown.

Results: We have synthesized stable albumin NPs that demonstrate significantly greater uptake in cancer cells with activating mutations of *KRAS* than monomeric albumin (ie, dissociated form of clinically used nab-paclitaxel). From pharmacological inhibition and semi-quantitative fluorescent microscopy studies, these NPs exhibit significantly increased uptake in mutant *KRAS* cancer cells than wild-type *KRAS* cells by macropinocytosis.

Conclusions: The uptake of albumin nanoparticles is driven by *KRAS*. This NP-based strategy targeting *RAS*-driven macropinocytosis is a facile approach toward improved delivery into *KRAS*-driven cancers.

Keywords: albumin nanoparticles, *KRAS* mutation, macropinocytosis

Background

Mutations of the *RAS* oncogenes (*HRAS*, *NRAS*, and *KRAS*) are the most frequent mutations in human cancers and are present in 25% of all cancers. Among the three isoforms of *RAS* genes, *KRAS* is the most frequent mutated (85% in all *RAS*-driven cancers). In particular, hyperactivated mutations of *RAS* oncogenes initiate and drive tumor progression in a significant subset of lung, colorectal, and pancreatic cancers.¹ Patients with oncogenic *RAS* mutations have poor prognosis in colorectal and pancreatic cancers.^{2,3} As a result, drug delivery targeting *RAS*-driven tumors has been a long-standing goal for cancer therapy.^{1,4} However, targeting cancers with *RAS* mutations has been a significant challenge due to the poor therapeutic index of existing *RAS* inhibitors.¹ Consequently, approaches that enhance delivery and accumulation of *RAS*-targeting therapeutics would greatly advance and significantly improve patient outcomes.

Correspondence: Debadyuti Ghosh
College of Pharmacy, The University of
Texas at Austin, 2409 University Avenue,
Austin, TX 78712, USA
Tel +1 512 471 7390
Fax +1 512 471 7474
Email dghosh@austin.utexas.edu

RAS hyperactivation drives cancer cell survival and proliferation by altering metabolic requirements of the cells to upregulate intracellular uptake; as a result, mutant *RAS* drives the uptake of numerous solutes. *RAS* proteins are GTPases that act as “molecular switches”, effectively cycling between binding to guanosine triphosphatase (GTP) and guanosine diphosphatase (GDP).⁵ During homeostasis, *RAS* protein toggle between binding to GTP in its active state and GDP in its non-stimulated, inactive state. At rest, *RAS* protein is bound to GDP in its inactive state. Upon stimulation by growth factor cues, GDP is released and *RAS* binds to GTP, which subsequently activates downstream RAF/MEK/ERK signaling axis, resulting in cell proliferation. *RAS* activation also spurs on PI3K and RalGDS effectors, which also stimulate cell proliferation, migration, and survival.⁶ Then, GTPase activation protein stimulates the breakdown of GTP via hydrolysis, producing GDP to bind and inactivate *RAS*. During tumorigenesis, specific mutations of *RAS* cause constitutive *RAS*-GTP binding and subsequent constitutive activation of downstream effectors resulting in uncontrollable cell proliferation and survival.⁶

Here, oncogenic *RAS* reprograms downstream signaling and alters cellular metabolism to fulfill the nutrient requirements of these actively proliferating cancer cells. *RAS*-transformed cells activate RAF/MEK/ERK signaling to increase glycolysis,^{7,8} non-oxidative pentose phosphate pathway,⁷ and hexosamine biosynthesis pathways,⁹ which increase biomass synthesis needed for cell survival and proliferation. In addition, cells have evolved to use available sources of lipids, proteins, and nutrients for cell survival and proliferation. *RAS*-driven cancers can scavenge nutrients intracellularly and extracellularly for their survival. Oncogenic *RAS* proteins stimulate macropinocytosis in quiescent fibroblasts¹⁰ and cancer cells^{11–13} to “drink” in surrounding bulk fluid and scavenge extracellular lipids and proteins. *HRAS* overexpressing embryonic fibroblasts and *RAS*-transformed cells demonstrate increased membrane ruffling characteristic of macropinocytosis and higher intracellular content of lysophospholipids.^{10,14} Macropinocytosis is a fluid-phase endocytic process whereby cells form membrane ruffles upon extracellular or intracellular cues, resulting in the formation of large diameter vacuoles (0.2–5 μm), or macropinosomes, that are able to transport solutes intracellularly.^{15,16} *RAS*-transformed cells use the macropinocytosis program to fulfill their metabolic dependency to maintain their growth and survival. Lipids, glutamine, and in particular albumin have been actively scavenged by *RAS*-transformed fibroblasts, breast, and pancreas cancers

harboring activating *RAS* mutations.^{11–13,17,18} Collectively, these findings strongly indicate that albumin is actively macropinocytosed by *RAS*-transformed cells in vivo for metabolic needs. Toward this end, is it feasible to exploit this vulnerability of nutrient transport to deliver drug carriers?

Attempts have been reported to deliver therapeutic payloads encapsulated in exosomes and lipoprotein nanostructures to cancer cells via macropinocytosis.^{19–21} We hypothesize that albumin-based particles can exploit the macropinocytosis pathway of *RAS*-driven cancer cells for intracellular delivery. Albumin has been used as a carrier to deliver different drugs for various diseases including inflammation and cancer.²² In particular *nab-paclitaxel*, or albumin-complexed paclitaxel, has been shown in combination therapy to improve overall survival compared to monotherapy and is standard of care for the treatment of advanced pancreatic cancer.²³ While albumin has been used, it has not been developed to actively and explicitly used in mechanistic, macropinocytosis-driven delivery into mutant *KRAS*-specific cancers.

Here, cross-linked albumin nanoparticles (NPs) demonstrate enhanced uptake in oncogenic *RAS* cells compared to control cells with wild-type *RAS* by non-ligand mediated macropinocytosis. The physicochemical properties of the NPs are tunable and they are colloidal and physiologically stable. Interestingly, these particles exhibit greater uptake than equivalent amounts of monomeric albumin (ie, present in in vivo dissociated *nab-paclitaxel*). Through microscopy-based quantification, these NPs colocalize in macropinosomes. Through pharmacological inhibition and genetic knockdown experiments, we demonstrate that these NPs can be endocytosed via *RAS*-driven macropinocytosis. These collective findings demonstrate that the macropinocytosis pathway of oncogenic *RAS* cancer cells can be exploited for NP delivery. By understanding this mechanism between the specific cancer pathway and its impact on delivery, it will be feasible to develop drug carriers for pathway-specific, targeted delivery. This work has the impact to greatly improve upon drug delivery and targeting to *RAS*-driven cancers.

Materials and methods

Synthesis of serum albumin NPs

NPs were synthesized by modified desolvation methods.²⁴ Briefly, bovine serum albumin (BSA, Fraction V, Fisher Scientific) was dissolved in 10 mM sodium chloride

solution to make a 1.5% (w/v) BSA solution. The pH of the solution was adjusted to 9.0 with sodium hydroxide. The desolvation agent was a mixture of methanol and ethanol at the ratio of 7:3 (v/v). Then, 4 mL of the desolvation agent was added into 1 mL BSA solution using a syringe pump (KD Scientific) at 1 mL/min under constant stirring. Subsequently, 8% glutaraldehyde solution (Sigma-Aldrich) was added to the system to induce particle cross-linking. Cross-linking process was allowed under stirring at room temperature for 12 hrs. The synthesized NPs were washed with water for three times, using centrifugal filter membrane units (molecular weight cutoff 100 kDa, Amicon). Fluorescent fluorescein isothiocyanate (FITC, ThermoFisher Scientific) and Cyanine 7 (Cy7, Lumiprobe) was conjugated to monomeric BSA according to the manufacturer's protocol, respectively. Fluorescently labeled nanoparticles (FITC-NP and Cy7-NP) were synthesized by the same procedures as described above using FITC-BSA or Cy7-BSA instead of BSA.

Characterization of NPs

The hydrodynamic diameter and zeta potential of the synthesized NPs were characterized using Zetasizer Nano ZS (Malvern) with 173° backscatter angle. The morphology of the NPs was observed by a transmission electron microscope (TEM). NPs solution was spread on a carbon-coated grid and negatively stained with 2% uranyl acetate. The grid was air-dried and then observed by TEM (FEI Tecnai).

Cell lines and cell culture

Human breast cancer cell lines, MDA-MB-231 harboring oncogenic *KRAS* mutation and MDA-MB-468 with wild-type *KRAS*, were purchased from American Type Culture Collection. DMEM/high glucose medium (Corning) supplemented with 10% fetal bovine serum (Gibco) and 100 U/mL penicillin-streptomycin (Gibco) was used to maintain both cell lines. Cells were kept in a humidified atmosphere with 5% carbon dioxide at 37°C.

Measurement of intracellular uptake of NPs by flow cytometry

MDA-MB-231 and MDA-MB-468 cells were seeded in 24-well plates at a density of 4×10^5 cells/well, respectively. After attachment, cells were starved in serum-free medium overnight. To compare the difference in uptake of monomeric albumin and NPs, cells were, respectively, incubated with FITC-BSA and FITC-NP

for 2 hrs at different concentrations of 0.5, 1.0, and 1.5 mg/mL (equivalent amount of albumin). To evaluate the inhibitory effect of macropinocytic inhibitor 5-(N-ethyl-N-isopropyl) amiloride (EIPA, Sigma-Aldrich) on the uptake of NPs, cells were pre-treated with 25, 50, and 75 μ M EIPA for 30 mins, respectively. Then, cells were incubated with 500 μ g/mL FITC-NP for another 30 mins. After each treatment, cells were placed on ice and washed with ice-cold PBS for three times. Cells were collected in PBS buffer and stained with propidium iodide (PI, Sigma-Aldrich). Samples were then analyzed by a flow cytometer (Accuri, BD Biosciences). PI-positive cells were excluded as dead cells.

Measurement of macropinocytic index

Macropinocytotic index was measured by an image-based method with slight modification.^{25,26} Cells were plated in a 24-well plate with a circular cover glass in each well. Cells were incubated with serum-free medium overnight after reaching 60–70% confluency. The cells were incubated with 1 mg/mL tetramethylrhodamine (TMR)-dextran in serum-free medium for 30 mins. After treatment, cells were washed with ice-cold PBS for five times and fixed with 3.7% formaldehyde solution for 30 mins at room temperature. DAPI solution was added to stain the nucleus of the cells. The cover glass was then placed cell side down onto a glass slide with a drop of mounting medium. Cell images were randomly captured using an Olympus IX-83 inverted fluorescence microscope with a 100 $\times$ phase objective. A z-stack of frames throughout the entire height of cell monolayers was acquired. The z-stack images were then collapsed to a single image using extended focus imaging projection (CellSens 1.16). To calculate the macropinocytic index, the total cell area was first selected from phase contrast images using the polygon selection tool of ImageJ. Then, the region of interest was applied onto the corresponding TMR-dextran image with thresholding for macropinosomes. The total area of macropinosomes was computed. The macropinocytic index was calculated as the following: macropinocytotic index = total area of macropinosomes/cell number.

Colocalization of NPs with macropinosomes

To quantify the colocalization of NP with macropinosomes, cells were plated in the same way as described in

the measurement of the macropinocytic index. Then, cells were incubated with 1 mg/mL TMR-dextran and 1 mg/mL Cy7 labeled NPs simultaneously. A group of cells were treated with 25 μ M EIPA to evaluate the effect of macropinocytic inhibition on colocalization. After incubation, cells were fixed and sealed onto glass slides. Cell images were captured using an Olympus IX-83 inverted fluorescence microscope with a 100 $\times$ phase objective. A z-stack of frames throughout the entire height of cell monolayers was acquired. The z-stack images were then collapsed to a single image using extended focus imaging projection. Background was subtracted with a constant of 1500. For each channel, the contrast was adjusted to the same scale. The Pearson correlation coefficient (PCC) between pixels of TMR-dextran and pixels of Cy7 NPs was analyzed by Cellsense 1.16 (Olympus).

Knockdown of KRAS protein expression and NP uptake

MDA-MB-231 cells were seeded in six-well plates at a density of 1×10^6 cells/well. After 24 hrs, cells were transfected with siRNAs against *KRAS* gene (SMARTpool: Accell *KRAS* siRNA, Dharmacon) at a final concentration of 0.5, 1.0, and 1.5 μ M in Accell siRNA delivery media, respectively. A non-targeting siRNA was used as a negative control. One hundred and twenty hours after transfection, cells were harvested for Western blot analysis. Cells were lysed using RIPA buffer (Thermo Scientific) with protease inhibitor (Roche). The protein concentrations were determined by BCA protein assay reagent kit (Thermo Scientific). Equivalent amounts of lysates (20 μ g total protein per lane) were loaded and separated by 10% SDS-PAGE (Invitrogen Bolt Bis-Tris Plus gel). Then, proteins were transferred onto a low fluorescence PVDF membrane (Invitrogen). In order to probe *KRAS* and β -actin separately, the membrane was cut into two pieces according to the protein ladder and blocked with 5% non-fat milk. Then, the membranes were incubated with anti-*KRAS* antibody (Abcam 55,391) and anti- β -actin antibody (Sigma AC-40) at 4°C overnight, respectively, followed by washing and incubating with secondary antibody (IRDye 800 CW, LI-COR) at room temperature for 2 hrs. Finally, the protein bands were visualized using the Odyssey Clx imaging system (LI-COR). Densitometry measurements were calculated using the gel analysis tool in ImageJ.

To evaluate the intracellular uptake of NPs in cells with decreased *KRAS* expression, MDA-MB-231 cells were seeded in 24-well plates and transfected with 1.0 and 1.5 μ M Accell siRNAs, respectively. One hundred and twenty hours after transfection, cells were incubated with 500 μ g/mL FITC-NP for 30 mins and subsequently analyzed by flow cytometry using the same method as described above.

Statistical analysis

All experiments were performed in triplicate at minimum. Experiments to measure macropinocytic index and colocalization of NPs with macropinosomes were repeated 10 times. The results were expressed as means $\pm$ standard deviation. Statistical significance was analyzed using Students' *t*-test for mean differences among the samples.

Results

Physicochemical properties of NPs

Cross-linked albumin NPs were synthesized by desolvation method.^{24,27} The hydrodynamic size and charge of the NPs were characterized by dynamic light scattering and zeta potential measurements, respectively. The sizes of the NPs were controlled by changing the ratio of methanol and ethanol in the desolvation agent. As shown in Figure 1A, increasing the percentage of ethanol from 0% to 100% increased the mean diameter of the NPs from 36.13 ± 0.27 to 252 ± 0.172 nm. The polydispersity indexes of the NPs were all below 0.25, which suggest that the synthesis resulted in relatively monodisperse populations. The zeta potentials of the NPs ranged from -37.60 ± 0.53 to -46.67 ± 0.32 mV. There is no obvious trend correlating desolvation agent with charge of NPs (Figure 1B). The mean size of nanoparticles synthesized with desolvation agent of methanol: ethanol at the ratio of 7:3 (v/v) was 69.78 ± 0.43 nm with PDI of 0.13 ± 0.01 . The zeta potential of the NPs was -42.73 ± 1.20 mV. If the methanol:ethanol ratio was changed, either the size of NPs increased, or the size distribution broadened. Based on published literature regarding the size effects of NPs, small NPs not only extravasate and travel deep into tumor, but also have a higher probability to be internalized by cells.^{28,29} Thus, cross-linked NPs synthesized with the 7:3 methanol:ethanol ratio were chosen for subsequent experiments.

For subsequent studies to investigate cell uptake of particles, cross-linked albumin nanoparticles (FITC-NPs)

Figure 1 (A) Size and polydispersity index of nanoparticles synthesized at different EtOH (%). (B) Zeta potential of nanoparticles synthesized at different EtOH (%). (n=3). TEM images of (C) albumin nanoparticles and (D) FITC labeled nanoparticles.

Abbreviations: TEM, transmission electron microscope; FITC, fluorescent fluorescein isothiocyanate; EtOH, ethanol; PDI, polydispersity index.

were prepared using fluorescently labeled monomeric albumin to ensure cross-linked NPs had equivalent amount of FITC/albumin ratio as FITC-BSA. The mean size and zeta potential of the FITC-NPs were 71.41 ± 0.64 nm (PDI 0.10 ± 0.004) and -42.5 ± 0.36 mV, respectively. These measurements indicate that the conjugation of FITC to albumin prior to nanoprecipitation of cross-linked NPs did not

impact their physicochemical properties. Both non-labeled and FITC-labeled NPs were observed by transmission electron microscopy (Figure 1C and D, respectively).

The NPs had a spherical morphology and were evenly distributed. To confirm their physiological stability in vitro, particles were incubated in complete media with 10% FBS at 37°C. The size and PDI of

Figure 2 Stability of NPs incubated with 10% FBS in DMEM, (A) size and (B) PDI measured at predetermined time-points. (n=3).

Abbreviations: NPs, nanoparticles; FBS, fetal bovine serum; DMEM, Dulbecco's Modified Eagle's Medium; PDI, polydispersity index.

Figure 3 In vitro uptake of FITC-BSA and FITC-NPs in (A) MDA-MB-231 and (B) MDA-MB-468 cells. (n=3, * $p < 0.05$, ** $p < 0.01$).

Abbreviations: FITC, fluorescein isothiocyanate; BSA, bovine serum albumin; NP, nanoparticles.

NPs (Figure 2A and B, respectively) had a negligible change up to 5 days, which confirms their serum stability.

NPs demonstrate higher uptake than monomeric albumin

Intracellular uptake of FITC-BSA and FITC-NPs was evaluated in MDA-MB-231 cells with oncogenic *KRAS* mutation G13D (Figure 3A) and control MDA-MB-468 cells with wild-type *KRAS* alleles (Figure 3B). Equivalent amounts of FITC-BSA and FITC-NPs were incubated, and uptake of these fluorescent particles was quantified by flow cytometry. As shown in Figure 3, the mean fluorescence intensity (MFI) of FITC-BSA and FITC-NPs in both cell lines increased in a dose-dependent manner. However, at each dose, the MFI of cells treated by FITC-NPs was significantly higher than those of cells treated by FITC-BSA. In mutant *KRAS* MDA-MB-231 cells incubated with 0.5, 1.0, and 1.5 mg/mL monomeric albumin or NPs, the uptake of albumin NPs was 1.37, 1.31, and 1.29-fold higher than that of monomers, respectively. In MDA-MB-468 cells incubated with 0.5, 1.0, and 1.5 mg/mL monomeric albumin or NPs, the uptake of albumin NPs was 1.15, 1.25, and 1.76-fold higher than that of monomeric albumin, respectively. The results indicated that cross-linked NPs demonstrate greater uptake than monomeric albumin.

Cross-linked albumin may stabilize and improve upon existing *nab-paclitaxel*; upon systemic administration, *nab-paclitaxel* dissociates from particulate form into monomeric albumin and thereby limits the amount of drug delivery without incurring systemic toxicities.^{17,18,30}

From the MFI values in Figure 3, oncogenic *KRAS* MDA-MB-231 cells exhibited greater uptake of both monomeric albumin and cross-linked albumin NPs than control MDA-MB-468 cells ($p < 0.01$). The uptake of FITC-NPs by MDA-MB-231 cells was 1.74, 1.69, and 1.16-fold as the uptake in MDA-MB-468 cells at 0.5, 1.0, and 1.5 mg/mL, respectively. Subsequent experiments were performed to support that activating mutations of *RAS* stimulate greater particle uptake than in cells with wild-type *KRAS* alleles.

Decreased *KRAS* protein expression resulted in reduced intracellular uptake of NPs

It was next tested if activating *KRAS* stimulates NP uptake in cancer cells. MDA-MB-231 cells were transfected with siRNA targeting *KRAS*, and knockdown resulted in decreased *KRAS* protein expression, as indicated by immunoblotting (Figure 4A). As shown in Figure 4A, siRNA knockdown of *KRAS* in cells at different concentrations decreased *KRAS* expression compared to non-targeting siRNA treated cells. Using densitometry to semi-quantify protein expression, *KRAS* protein expression decreased to 50.4% with 1.5 μ M siRNA treatment. Subsequently, the intracellular uptake of FITC-NPs was determined in MDA-MB-231 cells with siRNA-mediated knockdown of *KRAS*. As shown in Figure 4B, there was no difference between cells without any treatment and cells treated with non-targeting siRNA. The addition of control siRNA did not affect the uptake of FITC-NPs. However, the uptake of FITC-NPs was significantly decreased in cells treated with *KRAS*-targeting siRNAs, which indicates that direct inhibition of *KRAS* can negatively impact uptake of FITC-

Figure 4 (A) Protein expression of *KRAS* and β -actin in MDA-MB-231 cells harvested 120-hr post-transfection by siRNA. Normalized values of the densitometric measurements are listed in the figure. **(B)** Relative uptake of FITC-NPs by MDA-MB-231 cells 120-hr post-transfection by siRNA. (n=3, * p <0.05, ** p <0.01).

NPs. This finding supports previous studies that demonstrated hyperactivating *RAS* in cells stimulates their uptake of macromolecules.^{10,11,13}

Elevated macropinocytosis of NP uptake in oncogenic *KRAS* cells

It was then confirmed that oncogenic *KRAS* MDA-MB-231 exhibited increased macropinocytosis compared to cells with wild-type *RAS*. The macropinocytic activity of MDA-MB-231 cells and MDA-MB-468 cells was visualized by imaging the uptake of TMR-dextran, a fluorescent tracer for macropinocytosis. Here, TMR-dextran was internalized into cells via macropinosomes, shown as red puncta in Figure S1 (Supplementary material). The amount of macropinosomes, which correlates with the extent of macropinocytosis, was quantified by calculating their macropinocytic index, as developed by Comisso et al.²⁵ As shown in Figure S1, the relative uptake of TMR-dextran in MDA-MB-231 cells was 2.5-fold higher than in MDA-MB-468 cells (p <0.01). Greater uptake of TMR-dextran in oncogenic *KRAS* cells was due to macropinocytosis, as confirmed with pharmacological inhibition of EIPA, a canonical inhibitor of macropinocytosis (Figure S1). After treatment with 25 μ M EIPA, the relative macropinocytic index of MDA-MB-231 cells significantly decreased (p <0.01). However, there was no statistical difference in TMR-dextran uptake of MDA-MB-468 cells with or without EIPA (Figure S1). These results confirm that mutant *KRAS* cancer cells exhibit greater macropinocytosis than cells with wild-type *KRAS* alleles.

After confirming oncogenic *KRAS* MDA-MB-231 macropinocytosis tracer TMR-dextran, it was next confirmed that the uptake of our cross-linked albumin NPs is inhibited by a similar mechanism. As shown in Figure 5, when MDA-MB-231 cells were treated with 25, 50, and 75 μ M EIPA, the uptake of FITC-NPs was significantly inhibited by 16.79%, 21.50%, and 16.03%, respectively. For MDA-MB-468 cells (Figure 5), the inhibition percentages were 6.09%, 9.39%, and 18.40%, respectively. A larger percentage of FITC-NPs was inhibited by EIPA in MDA-MB-231 cells harboring oncogenic *KRAS* mutation compared to MDA-MB-468 cells with wild-type *KRAS*. The decrease in uptake due to the EIPA inhibition indicates that cross-linked albumin NPs can be endocytosed by macropinocytosis, and this decrease is more pronounced in mutant *KRAS* cells; this finding is comparable to other reports demonstrating increased albumin uptake by oncogenic *KRAS* cancer cells and tumors via macropinocytosis.^{7,11,12}

Colocalization of NPs with macropinosomes in oncogenic *KRAS* cells

To further confirm that albumin NPs were present in macropinosomes, which are indicative of macropinocytic uptake, Cy7 labeled NPs were synthesized for the colocalization analysis. The hydrodynamic size and zeta potential of Cy7 NPs were 62.22 ± 0.55 nm and -45.70 ± 0.42 mV. Colocalization of Cy7 NPs with TMR-dextran is shown in Figure 6. As shown in Figure 6A, Cy7 NPs (green) and TMR-dextran (red) were both taken up by mutant *KRAS* MDA-MB-231 cells. After treatment with EIPA (Figure 6B), the amount of red and green puncta both decreased,

Figure 5 EIPA inhibited uptake of FITC-NPs in MDA-MB-231 cells and MDA-MB-468 cells. (n=3, * $p<0.05$, ** $p<0.01$).

indicating the uptake of TMR-dextran and Cy7 NPs was decreased. In Figure 6C and D, the uptake level of Cy7 NPs and TMR-dextran was similar in MDA-MB-468 cells, regardless of the EIPA inhibition. To determine the localization of albumin NPs in macropinosomes, we quantitatively correlated the colocalization of NPs with TMR-dextran marker via image analysis and calculation of the PCC. The PCC values between the two channels were summarized in Figure 6E. The PCC value for MDA-MB-231 cells was 0.82, which indicates good correlation of pixel intensity distribution between red and green channels. After EIPA inhibition, the PCC value for MDA-MB-231 significantly decreased to 0.49 ($p<0.05$), which means there was a significant decrease of NP uptake by macropinocytosis. The relative low PCC values in

MDA-MB-468 cells indicated that the Cy7 NPs did not colocalize well with TMR-dextran as those in MDA-MB-231 cells. In other words, the fraction of NPs taken up by macropinocytosis was lower than that in oncogenic *KRAS* MDA-MB-231 cells.

Discussion

Oncogenic *RAS*, the most abundant overall mutation in cancers, programs cell signaling pathways and tumor progression; however, drugging this difficult-to-target oncoprotein has been the promise and a long-standing goal in cancer therapy. Hyperactive *RAS* triggers intake of extracellular nutrients needed for biogenesis, cancer cell survival, and proliferation to worsen tumor progression. Studies demonstrated that mice with pancreatic tumors possessing *KRAS* mutations demonstrated greater uptake of radiolabeled mouse serum albumin than healthy pancreas and wild-type *KRAS* pancreatic cancers.^{11,12} This increased uptake of albumin has also been previously observed with *RAS*-transformed fibroblasts^{10,11} and glioblastoma.³¹ Further, it was found that scavenged and catabolized extracellular albumin was the only source of amino acids present in oncogenic *KRAS* tumors and was needed for cancer cell proliferation and DNA synthesis.¹² Davidson et al, confirmed that albumin was macropinocytosed by oncogenic *KRAS* tumors and then degraded in lysosomes in vivo.¹² In addition to albumin and lipid uptake by oncogenic *KRAS* cells via macropinocytosis,^{11-13,17} it has been recently demonstrated that larger-sized solutes, including antibodies²¹ and lipoprotein NPs,²⁰ also exhibit increased uptake in hyperactive

Figure 6 Extended focus images of intracellular uptake of TMR-dextran (red) and Cy7-NPs (green): (A) MDA-MB-231 cells; (B) MDA-MB-231 cells treated with 25 μM EIPA; (C) MDA-MB-468 cells; (D) MDA-MB-468 cells treated with 25 μM EIPA. (E) Pearson correlation coefficient of Cy7-NPs vs TMR-dextran in MDA-MB-231 and MDA-MB-468 cells. (n=10, ** $p<0.01$).

Abbreviation: n.s, no significant difference.

RAS-stimulated cells via macropinocytosis. Constitutively active *RAS* stimulates intracellular uptake of lipids and proteins through the endocytic route of macropinocytosis, which facilitates transport of large solutes in vesicles up to 5 μ m in diameter.

Leveraging the metabolic needs of cancers for solute uptake via macropinocytosis, we wanted to develop NPs that specifically target this mechanism present in *RAS*-transformed or oncogenic cancer cells toward drug delivery. Building on prior studies demonstrating albumin uptake and catabolism in mutant *KRAS* cancers, we synthesized stable albumin NPs and tested their ability to enter oncogenic *KRAS* cancer cells for intracellular delivery. We confirmed that albumin NPs exhibit significantly enhanced uptake in oncogenic *KRAS* cancer cells compared with control cells with wild-type *KRAS*. Through extensive pharmacological inhibition, genetic knockdown, and microscopy studies, we demonstrated hyperactivated *KRAS* is responsible for stimulating macropinocytosis to engulf albumin NPs. By targeting oncogenic *RAS*-driven macropinocytosis for delivery, there is no need for conjugated ligands on the drug delivery system to facilitate cell binding and internalization. This simplicity of the nanoprecipitation synthesis and lack of conjugation chemistries avoids the challenges of chemistry and scalability and highlights the potential of this carrier for translation.^{32,33}

Interestingly, albumin NPs demonstrated significantly improved uptake compared to the equivalent amount of albumin monomers in cancer cell lines and in particular oncogenic *KRAS* MDA-MB-231 cells. The current gold standard in albumin-drug carriers, *nab-paclitaxel*, is a 130 nm paclitaxel-loaded albumin NP in formulation;³⁴ however, upon systemic administration, the particle rapidly dissociates into albumin monomers equivalent to endogenous albumin, and the drug prematurely releases, resulting in promiscuous accumulation in non-tumor tissues and organs and off-target toxicities.^{17,18,30} Even though macropinocytic activity and uptake of monomeric albumin-drug conjugate were observed in noncancerous and cancer cells with wild-type *RAS*, both were significantly lower than oncogenic *KRAS* cells. An albumin-drug conjugate was shown to demonstrate improved therapeutic efficacy in mutant *KRAS* xenografts compared to wild-type *KRAS* xenografts via macropinocytosis.³⁵ Coupled with the information that the cross-linked albumin NPs are stable in serum for several days, these findings suggest that cross-linked albumin NPs could deliver a

higher amount of albumin and potentially, drug, than non-covalent, monomeric albumin-associated *nab-paclitaxel*. While these albumin NPs improved uptake in mutant *RAS* cancer cells compared to controls, future studies against noncancerous cells are needed to confirm cell specificity. Additional studies will be needed to confirm drug encapsulation and stability of the cross-linked particles and compare its efficacy to *nab-paclitaxel* in cell culture and tumors.

Here, breast cancer cell line MDA-MB-231 is known to harbor a single point mutation at *KRAS* G13D, while MDA-MB-468 possess wild-type *KRAS*. The expression levels of total *RAS* are similar between the two cell lines.³⁶ As a result, from our studies, increased uptake of NPs in MDA-MB-231 is likely due to the mutant *KRAS*. Although the *KRAS* mutation is not present in the majority of breast cancers (<5%), considerable evidence has been reported that aberrant *RAS* activation and signaling can promote breast cancer development.³⁶ Finally, these NPs were formulated to actively target the macropinocytic pathway for intracellular uptake in oncogenic *RAS* cancers; to fulfill the promise of these NPs for *RAS*-targeted therapy, it will be necessary to extend delivery to additional cancers with more canonical *RAS* mutations (eg, *KRAS* G12V, G12C; *NRAS* G12D) than the cells used in this current study and to use *RAS*-targeted therapeutics such as covalent inhibitors,^{37,38} stapled peptides,³⁹ and other downstream Raf/MEK/ERK inhibitors.¹

Conclusion

In this work, the synthesized cross-linked albumin NPs exhibit significant uptake in oncogenic *KRAS* cancer cells compared with control wild-type *KRAS* cells. Oncogenic *KRAS* mutation is responsible for driving macropinocytosis to engulf albumin NPs. This initial step to use stable albumin-based particles to exploit the metabolic vulnerability of oncogenic *RAS* for intracellular uptake opens new avenues for macropinocytic-driven drug delivery targeting the formidable barrier of oncogenic *RAS*-driven cancers.

Acknowledgment

This work was supported by startup funds generously provided by The University of Texas at Austin College of Pharmacy.

Disclosure

The authors report no conflicts of interest in this work.

References

- Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? *Nat Rev Drug Discov*. 2014;13(11):828–851. doi:10.1038/nrd4389
- Tao LY, Zhang LF, Xiu DR, Yuan CH, Ma ZL, Jiang B. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis. *World J Surg Oncol*. 2016;14:146. doi:10.1186/s12957-016-0888-3
- Rui Y, Wang C, Zhou Z, Zhong X, Yu Y. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. *Hepatogastroenterology*. 2015;62(137):19–24.
- McCormick F. K-Ras protein as a drug target. *J Mol Med (Berl)*. 2016;94(3):253–258. doi:10.1007/s00109-016-1382-7
- Milburn MV, Tong L, deVos AM, et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. *Science*. 1990;247(4945):939–945. doi:10.1126/science.2406906
- Simanshu DK, Nissley DV, McCormick F. Proteins RAS. Their regulators in human disease. *Cell*. 2017;170(1):17–33. doi:10.1016/j.cell.2017.06.009
- Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell*. 2012;149(3):656–670. doi:10.1016/j.cell.2012.01.058
- Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature*. 2013;496(7443):101–105. doi:10.1038/nature12040
- Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. *Front Biosci (Elite Ed)*. 2012;17:670–699.
- Bar-Sagi D, Feramisco JR. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. *Science*. 1986;233(4768):1061–1068. doi:10.1126/science.3090687
- Commisso C, Davidson SM, Soydaner-Azeloglu RG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. *Nature*. 2013;497(7451):633–637. doi:10.1038/nature12138
- Davidson SM, Jonas O, Keibler MA, et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. *Nat Med*. 2017;23(2):235–241. doi:10.1038/nm.4256
- Kamphorst JJ, Nofal M, Commisso C, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. *Cancer Res*. 2015;75(3):544–553. doi:10.1158/0008-5472.CAN-14-2211
- Kamphorst JJ, Cross JR, Fan J, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. *Proc Natl Acad Sci U S A*. 2013;110(22):8882–8887. doi:10.1073/pnas.1307237110
- Hewlett LJ, Prescott AR, Watts C. The coated pit and macropinocytic pathways serve distinct endosome populations. *J Cell Biol*. 1994;124(5):689–703. doi:10.1083/jcb.124.5.689
- Doherty GJ, McMahon HT. Mechanisms of endocytosis. *Annu Rev Biochem*. 2009;78:857–902. doi:10.1146/annurev.biochem.78.081307.110540
- Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The utilization of extracellular proteins as nutrients is suppressed by mTORC1. *Cell*. 2015;162(2):259–270. doi:10.1016/j.cell.2015.06.017
- Tanei T, Leonard F, Liu X, et al. Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases. *Cancer Res*. 2016;76(2):429–439. doi:10.1158/0008-5472.CAN-15-1576
- Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. *Nature*. 2017;546(7659):498–503. doi:10.1038/nature22341
- Huang JL, Jiang G, Song QX, et al. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. *Nat Commun*. 2017;8:15144. doi:10.1038/ncomms15144
- Ha KD, Bidlingmaier SM, Zhang Y, Su Y, Liu B. High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies. *Mol Cell Proteomics*. 2014;13(12):3320–3331. doi:10.1074/mcp.M114.039768
- Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. *Mol Cell Ther*. 2016;4:3. doi:10.1186/s40591-016-0048-8
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369
- von Storp B, Engel A, Boeker A, Ploeger M, Langer K. Albumin nanoparticles with predictable size by desolvation procedure. *J Microencapsul*. 2012;29(2):138–146. doi:10.3109/02652048.2011.635218
- Commisso C, Flinn RJ, Bar-Sagi D. Determining the macropinocytic index of cells through a quantitative image-based assay. *Nat Protoc*. 2014;9(1):182–192. doi:10.1038/nprot.2014.004
- Wang JTH, Teasdale RD, Liebl D. Macropinosome quantitation assay. *MethodsX*. 2014;1:36–41. doi:10.1016/j.mex.2014.05.002
- Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. *Int J Pharm*. 2000;194(1):91–102.
- Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. *Annu Rev Biomed Eng*. 2012;14:1–16. doi:10.1146/annurev-bioeng-071811-150124
- Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: size matters. *J Nanobiotechnology*. 2014;12:5. doi:10.1186/1477-3155-12-5
- Bhattacharyya J, Bellucci JJ, Weitzhandler I, et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms abraxane in multiple murine cancer models. *Nat Commun*. 2015;6:7939. doi:10.1038/ncomms8939
- Overmeyer JH, Kaul A, Johnson EE, Maltese WA. Active ras triggers death in glioblastoma cells through hyperstimulation of macropinocytosis. *Mol Cancer Res*. 2008;6(6):965–977. doi:10.1158/1541-7786.MCR-07-2036
- Elias DR, Poloukhine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. *Nanomedicine*. 2013;9(2):194–201. doi:10.1016/j.nano.2012.05.015
- Hare JJ, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. *Adv Drug Deliv Rev*. 2017;108:25–38. doi:10.1016/j.addr.2016.04.025
- Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. *Clin Cancer Res*. 2006;12(4):1317–1324. doi:10.1158/1078-0432.CCR-05-1634
- Liu H, Sun M, Liu Z, et al. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. *J Controlled Release*. 2019;296:40–53. doi:10.1016/j.jconrel.2019.01.014
- Eckert LB, Repasky GA, Ülkü AS, et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. *Cancer Res*. 2004;64(13):4585–4592. doi:10.1158/0008-5472.CAN-04-0396
- Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. *Nat Rev Drug Discov*. 2016;15(11):771–785. doi:10.1038/nrd.2016.139

38. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature*. 2013;503(7477):548–551. doi:10.1038/nature12796
39. Leshchiner ES, Parkhitko A, Bird GH, et al. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. *Proc Natl Acad Sci U S A*. 2015;112(6):1761–1766. doi:10.1073/pnas.1413185112

Supplementary material

Figure S1 Macropinocytosis of TMR-dextran (red) in cells (nuclei in blue) observed by fluorescence microscopy. (A) MDA-MB-231 cells without EIPA treatment; (B) MDA-MB-231 cells treated with 25 µM EIPA; (C) MDA-MB-468 cells without EIPA treatment; (D) MDA-MB-468 cells treated with 25 µM EIPA. (E) Relative macropinocytotic index of cells. (n=10, ** $p < 0.05$, n.s. is no significant difference)

Abbreviations: TMR, tetramethylrhodamine; EIPA, 5-(N-ethyl-N-isopropyl)amiloride.

International Journal of Nanomedicine

Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Journal Citation Reports/Science Edition, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>